|Bid||94.61 x 800|
|Ask||96.49 x 800|
|Day's Range||95.42 - 96.54|
|52 Week Range||69.18 - 99.84|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||30.98|
|Forward Dividend & Yield||3.09 (3.26%)|
|Ex-Dividend Date||Mar 03, 2020|
|1y Target Est||N/A|
Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.